Tag: FDA

A total of 110 posts are filed under FDA
Keytruda 50mg/vial
2014
Rare Disease Report: FDA Expands Keytruda Indication for Advanced Melanoma
The FDA has approved an expanded indication for Keytruda (pembrolizumab), an anti-PD-1 (programmed death receptor-1) therapy, to include it… Continue Reading
CureDuchenne__Logo_No_Background-1024x427
CureDuchenne Responds to FDA Advisory Committee Meeting on Drisapersen for Duchenne Muscular Dystrophy
CureDuchenne, the California-based nonprofit organization dedicated to finding cures for Duchenne muscular dystrophy, released the… Continue Reading
Rett Syndrome_news story image
FDA Awards KGI an Orphan Drug Designation for Rett Syndrome
A project that was part of Dr. Ian Phillips’ Writing an Orphan Drug Application (ALS 432) class recently led to the U.S. Food and Drug… Continue Reading
The corporate logo of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. U.S. health officials unveiled plans to fight avoidable injuries from medication errors or misuse, a problem that harms hundreds of thousands of people each year and can be deadly.    REUTERS/Jason Reed   (UNITED STATES HEALTH) - RTXQCTX
Rare Disease Report: FDA Approves Combination Letairis and Adcirca for PAH
The U.S. Food and Drug Administration (FDA) has approved the combination of Letairis (ambrisentan) and Adcirca (tadalafil) to treat patients… Continue Reading
img_5145588fecc15
FDA Awards 18 Grants to Stimulate Product Development for Rare Diseases
The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the… Continue Reading
Screen Shot 2015-08-17 at 2.53.55 PM
Rare Disease Report: Raptor’s Cysteamine Capsule Now Approved for Children
Children with nephropathic cystinosis can now receive delayed-release cysteamine tablets. Raptor Pharmaceutical Corp announced that the U.S.… Continue Reading
Genentech
Genentech on the Verge of First Biologic Treatment for Pemphigus Vulgaris
Genentech has announced the initiation of a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus… Continue Reading
be-a-guest-blogger

Follow us on Twitter